Cardiac sympathetic innervation imaging in patients with trastuzumab induced cardiotoxicity - CARIT

eids Universitair Medisch Centrum0 个研究点目标入组 30 人开始时间: 待定最近更新: 2024年8月12日

适应症

试验速览

暂无简介。

•Adult patients with confirmed HER-2 positive breast cancer (immunohistochemistry score 3 or fluorescence in-situ hybridization positive) who have completed local regional therapy and treatment with trastuzumab or are still on treatment with trastuzumab.
•Permanent LVEF <=50% after treatment with trastuzumab, and/or
•A permanent relative decrease of >=10% from baseline measured by means of echocardiography or MUGA scan and confirmed after 3 weeks after/during treatment with trastuzumab, and/or
•Symptomatic congestive heart failure defined as NYHA class III/IV
•Age 18-80 years.
•Signed informed consent
•Amendement: Add control group: patients without a permanent relative decrease of >=10% from baseline measured by means of echocardiography or MUGA scan and confirmed after 3 weeks after/during treatment with trastuzumab, and/or symptomatic congestive heart failure defined as NYHA class III/IV

•Pre-existing cardiac disease such as heart failure, ischemic and valvular heart disease, arrhythmia or poorly controlled hypertension.
•Concomitant inflammatory disease.
•Pregnancy/beast feeding.
•Allergy against radiopharmaceutical (99m Tc-based tracer) for MUGA scan.

发起方